Clinical Trial of Low-dose Radiation Therapy in Patients With Knee Osteoarthritis (LoRD-KNeA Trial)

Sponsor

Seoul National University Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05562271

Collaborator

Samsung Medical Center (Other), SMG-SNU Boramae Medical Center (Other), Korea Hydro & Nuclear Power (Other)

114

Enrollment

Location

Arms

Anticipated Duration (Months)

4.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Clinical verification of knee osteoarthritis pain relief and functional improvement using low-dose radiation therapy

Condition or Disease	Intervention/Treatment	Phase
Knee Osteoarthritis	Radiation: low-dose radiation therapy Radiation: sham radiation therapy	N/A

Detailed Description

This clinical trial is a multicenter, randomized, single-blinded, exploratory clinical trial to evaluate the efficacy and safety of low-dose radiation for knee osteoarthritis patients. The experimental group is treated with low-dose irradiation 6 times for 3 weeks according to the dose determined for each group, and the control group is treated with sham irradiation. Both the experimental group and the control group visit the hospital 4 weeks after irradiation and at 4, 8, and 12 months to evaluate the efficacy and safety.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

114 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Participant)

Primary Purpose:

Treatment

Official Title:

A Multi-center, Randomized, Single-blinded, Exploratory Clinical Trial to Evaluate Safety and Efficacy of Alleviating Symptom of Low-dose RaDiation Therapy in Patients With KNee osteoArthritis

Anticipated Study Start Date :

Oct 1, 2022

Anticipated Primary Completion Date :

Sep 1, 2023

Anticipated Study Completion Date :

Dec 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Sham Comparator: sham radiation therapy sham radiation therapy	Radiation: sham radiation therapy sham radiation therapy to involved knee joint
Experimental: low-dose radiation therapy, 30 cGy/6 fx (experimental 1) low-dose radiation therapy, 30 cGy/6 fx	Radiation: low-dose radiation therapy low-dose radiation therapy to involved knee joint
Experimental: low-dose radiation therapy, 300 cGy/6 fx (experimental 2) low-dose radiation therapy, 300 cGy/6 fx	Radiation: low-dose radiation therapy low-dose radiation therapy to involved knee joint

Arm

Intervention/Treatment

Sham Comparator: sham radiation therapy

sham radiation therapy

Radiation: sham radiation therapy

sham radiation therapy to involved knee joint

Experimental: low-dose radiation therapy, 30 cGy/6 fx (experimental 1)

low-dose radiation therapy, 30 cGy/6 fx

Radiation: low-dose radiation therapy

low-dose radiation therapy to involved knee joint

Experimental: low-dose radiation therapy, 300 cGy/6 fx (experimental 2)

low-dose radiation therapy, 300 cGy/6 fx

Radiation: low-dose radiation therapy

low-dose radiation therapy to involved knee joint

Outcome Measures

Primary Outcome Measures

OMERACT-OARSI response rate [4 months]
OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Research Society International) response rate at 4 months. The OMERACT-OARSI criteria for response are (1) improvement in pain or physical function ≥50% and an absolute change ≥20 mm; or (2) improvement of ≥20% with an absolute change ≥10 mm in at least two of the following three categories: pain, physical function, and patient's global assessment.

Secondary Outcome Measures

OMERACT-OARSI response rate [4 weeks, 8 months, 12 months]
OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Research Society International) response rate at 4 weeks, 8 months, and 12 months. The OMERACT-OARSI criteria for response are (1) improvement in pain or physical function ≥50% and an absolute change ≥20 mm; or (2) improvement of ≥20% with an absolute change ≥10 mm in at least two of the following three categories: pain, physical function, and patient's global assessment.
Changes in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score [4 weeks, 4 months, 8 months, 12 months]
Total score (min 0, max 96 points, higher scores mean a worse outcome) and WOMAC score subscale (pain: min 0 max 20, stiffness: min 0 max 8, physical function: min 0 max 68)
Changes in pain score [4 weeks, 4 months, 8 months, 12 months]
VAS score (min 0, max 100, higher scores mean a worse outcome)
Changes in global assessment [4 weeks, 4 months, 8 months, 12 months]
PGA (Patient Global Assessment) score (min 0, max 100, higher scores mean a worse outcome)
Radiological Changes Evaluated by Knee MRI [4 months, 12 months]
Radiological Changes Evaluated by Knee MRI
Radiological Changes Evaluated by Knee X-ray [12 months]
Radiological Changes Evaluated by Knee X-ray
Changes in serum ESR (Erythrocyte sedimentation rate) [4 weeks, 4 months, 8 months, 12 months]
Changes in ESR (Erythrocyte sedimentation rate)
Changes in serum CRP (C-reactive protein) [4 weeks, 4 months, 8 months, 12 months]
Changes in CRP (C-reactive protein)
Change in the amount of analgesic rescue medication usage [4 weeks, 4 months]
Concomitant use of analgesics is prohibited until 4 months after irradiation, when the primary efficacy evaluation is scheduled. During this period, the use of a rescue drug (acetaminophen) may be permitted if the subjects need it for osteoarthritis. Monitor the amount of rescue medication prescribed to measure changes in usage during visits up to 4 months

Eligibility Criteria

Criteria

Ages Eligible for Study:

60 Years to 85 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 60-85 years old
Kellgren-Lawrence grade 2-3 and diagnosed as a patient with primary knee osteoarthritis according to the ACR knee OA diagnostic criteria
Patients with VAS 40 or higher when walking, with or without medication at the time of screening
Patients who have VAS 50 or more and 90 or less when walking at the baseline
Among patients who were previously taking analgesic drugs at the time of screening, those with an increase in pain of 10 points or more at the baseline
Patients who do not want to take non-narcotic analgesics, those who have failed to control their pain due to the use of non-narcotic analgesics, or candidates for invasive treatment (intra-articular injection, arthroplasty, etc.)
A person who has a will to discontinue all pain medications except for rescue medications throughout screening, baseline, and clinical trials related to knee arthritis
A person who gives consent to use an approved contraceptive method from screening to 3 months after the end of the clinical trial
A person who understands the eligibility requirements for the study and has signed the consent form

Exclusion Criteria:

A history of knee irradiation in the past
Patients participating in other degenerative arthritis clinical trials
Kellgren-Lawrence grade 4
A history of malignancy within the last 5 years
A history of knee or hip surgery in the past
Patients who have received systemic steroid treatment or intra-articular steroid/hyaluronic acid injection within 2 months of screening
Patients with hip degenerative arthritis or other diseases of NRS 5 or higher that may affect functional score evaluation
Patients who are scheduled for surgical treatment of the knee joint during the clinical trial period
BMI > 39 kg/m2
Known history of analgesic or substance abuse within 2 years of screening
History, diagnostic signs or symptoms of any of the following clinically significant psychiatric disorders that would render the study ineligible (psychotic disorder, depression, somatic disorder)
History, diagnostic signs, or symptoms of any of the following clinically significant heart diseases that would render the study ineligible (surgery or stenting for ischemic heart disease and coronary artery disease within 6 months prior to screening)
History of other diseases that may affect the index joint, including autoimmune diseases (lupus, rheumatoid arthritis, etc.)
Fibromyalgia history or diagnosis
If the researcher judges that a person with significant trauma or other findings considered clinically important is inappropriate for participation in this study